Reneuron Group (RENE)
RENE Share PerformanceMore
|52 week high||3.7125 25/05/16|
|52 week low||2.2500 04/11/16|
|52 week change||-1.0750 (-31.85%)|
|4 week volume||38,043,339 04/03/17|
Media for (RENE)
Latest News« previous» nextMore
01/03/2017 - 08:00 RNS
RNS Number: 1143Y ReNeuron Group plc 01 March 2017 1 March 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Block Listing Review and Total Voting Rights ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AI...
15/02/2017 - 08:00 RNS
RNS Number: 9216W ReNeuron Group plc 15 February 2017 15 February 2017 AIM: RENE RNS REACH ReNeuron Group plc ("ReNeuron" or the "Company") ReNeuron featured in BBC documentary "Andrew Marr: My Brain and Me" ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that its...
07/02/2017 - 15:15 StockMarketWire
Michael Hunt, Financial Director, bought 250,000 shares in the company on the 7th February 2017 at a price of 2.64p. The D...
07/02/2017 - 13:32 RNS
RNS Number: 2499W ReNeuron Group plc 07 February 2017 7 February 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Director Share Purchase ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 7 February 2017 that, on the same day, Michael Hunt , the Company...
01/02/2017 - 12:24 StockMarketWire
Michael Hunt, CFO of ReNeuron Group Plc (RENE) (LSE:RENE) will be giving a presentation at the exclusive Shares Inv...
14/12/2016 - 13:15 RNS
RNS Number: 8537R ReNeuron Group plc 14 December 2016 14 December 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Director Share Purchase ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 14 December 2016 that, on the same day, Olav Helleb, the Company'...
05/12/2016 - 10:40 StockMarketWire
ReNeuron has widened its H1 pretax loss to 8.6m, from a loss of 5.2m. Revenue was 22,000, from 11,000. Research and develo...
05/12/2016 - 10:38 StockMarketWire
ReNeuron Group announces positive data from its Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for s...
|Dividend yield||0 %|
Equity Research (RENE)
ReNeuron Group plc
ReNeuron reported in December 2016 positive Phase II trial data for its CTX cells in chronic stroke patients, despite not meeting the three-month time frame of a two-point improvement in its primary...
ReNeuron Group plc
ReNeuron has presented positive Phase II trial data for its CTX cells in chronic stroke patients. Reported data included 15 out of 21 patients having a clinically relevant and sustained response on...
ReNeuron Group plc
ReNeuron has announced the publication of long-term Phase I stroke clinical trial (PISCES-I) data in The Lancet. The data indicate improvements in neurological status and limb function compared with...
- 1 of 4
Latest discussion posts More
“Last post was not intended to be cynical as I appreciate the specialism on offer is heavily loaded to the startup of a new facility and usually handed over to other when up ...”▼
“Interesting CV with a spell at Zigzag associates immediately prior to joining Rene. Just get their feet under the table and off again. Wasn't like that in my day, thank ...”▼
“day 2 11.00 to 11.45 23/05/17 http://exlevents.com/european-clinical-trials-inspection-readiness-summit/agenda/ now you may be wondering what is relevance to us well ...”▼
Codes & Symbols
|Symbols||RENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE|